Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients

BACKGROUND & AIMS: Immunotherapy represents the new standard of care in systemic first-line treatment of hepatocellular carcinoma (HCC). Biomarkers that predict treatment response and survival remain an unmet clinical need. METHODS: Patients with HCC treated with immune-checkpoint inhibitors (IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Balcar, Lorenz, Bauer, David, Pomej, Katharina, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Trauner, Michael, Scheiner, Bernhard, Pinter, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081755/
https://www.ncbi.nlm.nih.gov/pubmed/37027398
http://dx.doi.org/10.1371/journal.pone.0282680

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10081755/
https://www.ncbi.nlm.nih.gov/pubmed/37027398
http://dx.doi.org/10.1371/journal.pone.0282680

Ejemplares similares